Ipsen, Spirogen, Celtic Therapeutics Holdings L.P. deal

Spirogen regained rights to SG2000 (formerly SJG-136) from Ipsen, which acquired development and commercialization rights to the compound in 2003. Ipsen is eligible for commercial milestones and royalties. Spirogen said the small molecule DNA minor groove binder is expected to start Phase II testing in ovarian and hematological cancers "shortly." Ipsen, which retains a 17% stake in Spirogen, said it is focused on hormone-dependent cancers (see BioCentury, June 30, 2003). ...